Trials / Completed
CompletedNCT00072631
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- OSI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
Detailed description
Only patients with 0 to 1 performance status on the ECOG scale are eligible.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarceva (Trademark) (erlotinib HCl, OSI-774) | Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash |
Timeline
- Start date
- 2003-11-05
- Primary completion
- 2007-03-14
- Completion
- 2007-03-14
- First posted
- 2003-11-07
- Last updated
- 2018-02-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00072631. Inclusion in this directory is not an endorsement.